Kalshi and Polymarket have launched markets that let users bet on whether specific drugs will win FDA approval. The move brings prediction market mechanics to a sensitive area of public health, drawing both interest and criticism. It's a new frontier for event contracts — and one that could reshape how biotech risk is traded.
How the markets work
Users on both platforms can buy contracts that pay out if a drug gets approved by a certain date. Kalshi, a CFTC-regulated exchange, offers cash-settled contracts. Polymarket, built on blockchain, uses USDC. The contracts cover a handful of high-profile drugs in late-stage trials. Think of it like betting on an election — but the outcome is a yes/no on a regulatory decision.
Ethical concerns
Critics argue that betting on drug approvals could create perverse incentives. If enough money rides on a negative outcome, could that influence trial conduct or public perception? Some worry it commodifies patient suffering. The timing isn't great — trust in drug pricing and approval processes is already fragile. These markets don't help.
Regulatory hurdles
The CFTC has previously cracked down on prediction markets it deems too close to gambling. Kalshi operates under CFTC oversight, so its contracts are subject to agency review. Polymarket, by contrast, runs on a decentralized blockchain, making it harder for US regulators to touch. That regulatory gap could become a flashpoint. The agency hasn't commented on these specific contracts yet.
Impact on biotech and crypto
For biotech, these markets offer a new hedging tool. A small drug developer could use them to gauge market sentiment on its own pipeline. For crypto, it's another real-world use case for decentralized prediction platforms — one that goes beyond sports and elections. But the ethical baggage might slow adoption. The CFTC's next move will set the tone for whether this becomes a standard product or a short-lived experiment.
